Annual CFO
-$68.62 M
+$7.10 M+9.38%
31 December 2023
Summary:
Xilio Therapeutics annual cash flow from operations is currently -$68.62 million, with the most recent change of +$7.10 million (+9.38%) on 31 December 2023. During the last 3 years, it has risen by +$12.13 million (+15.02%). XLO annual CFO is now -284.58% below its all-time high of -$17.84 million, reached on 31 December 2019.XLO Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFO
-$13.67 M
-$33.63 M-168.52%
30 September 2024
Summary:
Xilio Therapeutics quarterly cash flow from operations is currently -$13.67 million, with the most recent change of -$33.63 million (-168.52%) on 30 September 2024. Over the past year, it has dropped by -$245.00 thousand (-1.82%). XLO quarterly CFO is now -168.52% below its all-time high of $19.95 million, reached on 30 June 2024.XLO Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFO
-$17.65 M
-$303.00 K-1.75%
30 September 2024
Summary:
Xilio Therapeutics TTM cash flow from operations is currently -$17.65 million, with the most recent change of -$303.00 thousand (-1.75%) on 30 September 2024. Over the past year, it has increased by +$50.97 million (+74.28%). XLO TTM CFO is now -1.75% below its all-time high of -$17.34 million, reached on 30 June 2024.XLO TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
XLO Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | -1.8% | +74.3% |
| 3 y3 years | +15.0% | +20.3% | +78.2% |
| 5 y5 years | -284.6% | - | - |
XLO Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -90.1% | +15.0% | -168.5% | +45.9% | -1.8% | +78.2% |
| 5 y | 5 years | -284.6% | +15.0% | -168.5% | +45.9% | -1.8% | +78.2% |
| alltime | all time | -284.6% | +15.0% | -168.5% | +45.9% | -1.8% | +78.2% |
Xilio Therapeutics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$13.67 M(-168.5%) | -$17.65 M(+1.7%) |
| June 2024 | - | $19.95 M(-290.0%) | -$17.34 M(-67.8%) |
| Mar 2024 | - | -$10.50 M(-21.8%) | -$53.87 M(-21.5%) |
| Dec 2023 | -$68.62 M(-9.4%) | -$13.43 M(+0.4%) | -$68.62 M(-6.5%) |
| Sept 2023 | - | -$13.37 M(-19.3%) | -$73.42 M(-8.2%) |
| June 2023 | - | -$16.57 M(-34.4%) | -$79.96 M(-0.2%) |
| Mar 2023 | - | -$25.25 M(+38.6%) | -$80.14 M(+5.8%) |
| Dec 2022 | -$75.72 M | -$18.22 M(-8.5%) | -$75.72 M(+1.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2022 | - | -$19.91 M(+18.8%) | -$74.66 M(-1.1%) |
| June 2022 | - | -$16.76 M(-19.6%) | -$75.47 M(-4.3%) |
| Mar 2022 | - | -$20.84 M(+21.4%) | -$78.85 M(-2.4%) |
| Dec 2021 | -$80.75 M(+123.7%) | -$17.16 M(-17.2%) | -$80.75 M(+27.0%) |
| Sept 2021 | - | -$20.72 M(+2.9%) | -$63.59 M(+48.3%) |
| June 2021 | - | -$20.14 M(-11.4%) | -$42.87 M(+88.6%) |
| Mar 2021 | - | -$22.73 M | -$22.73 M |
| Dec 2020 | -$36.09 M(+102.3%) | - | - |
| Dec 2019 | -$17.84 M | - | - |
FAQ
- What is Xilio Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for Xilio Therapeutics?
- What is Xilio Therapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for Xilio Therapeutics?
- What is Xilio Therapeutics quarterly CFO year-on-year change?
- What is Xilio Therapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for Xilio Therapeutics?
- What is Xilio Therapeutics TTM CFO year-on-year change?
What is Xilio Therapeutics annual cash flow from operations?
The current annual CFO of XLO is -$68.62 M
What is the all time high annual CFO for Xilio Therapeutics?
Xilio Therapeutics all-time high annual cash flow from operations is -$17.84 M
What is Xilio Therapeutics quarterly cash flow from operations?
The current quarterly CFO of XLO is -$13.67 M
What is the all time high quarterly CFO for Xilio Therapeutics?
Xilio Therapeutics all-time high quarterly cash flow from operations is $19.95 M
What is Xilio Therapeutics quarterly CFO year-on-year change?
Over the past year, XLO quarterly cash flow from operations has changed by -$245.00 K (-1.82%)
What is Xilio Therapeutics TTM cash flow from operations?
The current TTM CFO of XLO is -$17.65 M
What is the all time high TTM CFO for Xilio Therapeutics?
Xilio Therapeutics all-time high TTM cash flow from operations is -$17.34 M
What is Xilio Therapeutics TTM CFO year-on-year change?
Over the past year, XLO TTM cash flow from operations has changed by +$50.97 M (+74.28%)